Black Bird Biotech, Inc. Logo

Black Bird Biotech, Inc.

BBBT

(2.2)
Stock Price

0,00 USD

-332.24% ROA

36.59% ROE

-0.44x PER

Market Cap.

178.543,00 USD

-81.07% DER

0% Yield

-1946.63% NPM

Black Bird Biotech, Inc. Stock Analysis

Black Bird Biotech, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Black Bird Biotech, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (159.79%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-0.07x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-84%), which means it has a small amount of debt compared to the ownership it holds

4 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

5 Net Profit Growth

This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity.

6 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

7 ROA

The stock's ROA (-1091.22%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Black Bird Biotech, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Black Bird Biotech, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Black Bird Biotech, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Black Bird Biotech, Inc. Revenue
Year Revenue Growth
2007 0
2008 0 0%
2009 0 0%
2010 691.600 100%
2011 1.116.880 38.08%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 17.771 100%
2020 57.604 69.15%
2021 104.458 44.85%
2022 82.563 -26.52%
2023 15.748 -424.28%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Black Bird Biotech, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Black Bird Biotech, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 26.638
2008 16.278 -63.64%
2009 168.723 90.35%
2010 187.403 9.97%
2011 166.051 -12.86%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 75.739 100%
2017 76.231 0.65%
2018 83.538 8.75%
2019 80.306 -4.02%
2020 677.995 88.16%
2021 1.355.823 49.99%
2022 997.908 -35.87%
2023 42.688 -2237.68%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Black Bird Biotech, Inc. EBITDA
Year EBITDA Growth
2007 -36.063
2008 -23.253 -55.09%
2009 -168.723 86.22%
2010 -225.766 25.27%
2011 -144.387 -56.36%
2012 -86.515 -66.89%
2013 -71.419 -21.14%
2014 -76.810 7.02%
2015 -85.916 10.6%
2016 -75.739 -13.44%
2017 -76.231 0.65%
2018 -83.538 8.75%
2019 -80.306 -4.02%
2020 -679.824 88.19%
2021 -1.341.470 49.32%
2022 -1.199.261 -11.86%
2023 166.820 818.9%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Black Bird Biotech, Inc. Gross Profit
Year Gross Profit Growth
2007 0
2008 0 0%
2009 0 0%
2010 38.238 100%
2011 82.890 53.87%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -31 100%
2020 29.359 100.11%
2021 19.587 -49.89%
2022 33.012 40.67%
2023 5.672 -482.02%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Black Bird Biotech, Inc. Net Profit
Year Net Profit Growth
2007 -36.063
2008 -23.253 -55.09%
2009 -168.723 86.22%
2010 -8.272.310 97.96%
2011 -160.159 -5065.06%
2012 -86.515 -85.12%
2013 -89.991 3.86%
2014 -99.519 9.57%
2015 -112.470 11.52%
2016 -106.268 -5.84%
2017 -110.014 3.41%
2018 -121.110 9.16%
2019 -163.628 25.98%
2020 -691.570 76.34%
2021 -2.096.629 67.02%
2022 -2.029.199 -3.32%
2023 -524.908 -286.58%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Black Bird Biotech, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 0
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Black Bird Biotech, Inc. Free Cashflow
Year Free Cashflow Growth
2006 -691.236
2007 -35.963 -1822.08%
2008 -23.128 -55.5%
2009 -159.948 85.54%
2010 -731.018 78.12%
2011 167.821 535.59%
2012 -67.166 349.86%
2013 -78.481 14.42%
2014 -81.556 3.77%
2015 -80.173 -1.73%
2016 -77.942 -2.86%
2017 -75.690 -2.98%
2018 -76.098 0.54%
2019 -86.325 11.85%
2020 -619.465 86.06%
2021 -998.130 37.94%
2022 -1.032.574 3.34%
2023 -4.900 -20972.94%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Black Bird Biotech, Inc. Operating Cashflow
Year Operating Cashflow Growth
2006 -691.236
2007 -35.963 -1822.08%
2008 -23.128 -55.5%
2009 -159.948 85.54%
2010 -731.018 78.12%
2011 167.821 535.59%
2012 -67.166 349.86%
2013 -78.481 14.42%
2014 -81.556 3.77%
2015 -80.173 -1.73%
2016 -77.942 -2.86%
2017 -75.690 -2.98%
2018 -76.098 0.54%
2019 -86.325 11.85%
2020 -619.465 86.06%
2021 -992.428 37.58%
2022 -1.032.574 3.89%
2023 -4.900 -20972.94%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Black Bird Biotech, Inc. Capital Expenditure
Year Capital Expenditure Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 5.702 100%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Black Bird Biotech, Inc. Equity
Year Equity Growth
2007 21.437
2008 3.184 -573.27%
2009 26.561 88.01%
2010 -132.782 120%
2011 -292.941 54.67%
2012 -379.456 22.8%
2013 -469.447 19.17%
2014 -568.966 17.49%
2015 -681.436 16.5%
2016 -787.704 13.49%
2017 -897.718 12.25%
2018 -1.018.828 11.89%
2019 -1.140.795 10.69%
2020 27.609 4231.97%
2021 670.210 95.88%
2022 -650.170 203.08%
2023 -922.778 29.54%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Black Bird Biotech, Inc. Assets
Year Assets Growth
2007 21.537
2008 3.409 -531.77%
2009 126.561 97.31%
2010 503.804 74.88%
2011 49.831 -911.03%
2012 22.665 -119.86%
2013 24.184 6.28%
2014 22.628 -6.88%
2015 12.455 -81.68%
2016 14.513 14.18%
2017 1.573 -822.63%
2018 4.733 66.77%
2019 973 -386.43%
2020 126.150 99.23%
2021 774.204 83.71%
2022 218.508 -254.31%
2023 98.779 -121.21%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Black Bird Biotech, Inc. Liabilities
Year Liabilities Growth
2007 100
2008 225 55.56%
2009 100.000 99.78%
2010 636.586 84.29%
2011 342.772 -85.72%
2012 402.121 14.76%
2013 493.631 18.54%
2014 591.594 16.56%
2015 693.891 14.74%
2016 802.217 13.5%
2017 899.291 10.79%
2018 1.023.561 12.14%
2019 1.141.768 10.35%
2020 98.541 -1058.67%
2021 103.994 5.24%
2022 868.678 88.03%
2023 1.021.557 14.97%

Black Bird Biotech, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-0.44x
Price To Sales Ratio
10.59x
POCF Ratio
-7.37
PFCF Ratio
-9.03
Price to Book Ratio
-0.16
EV to Sales
54.62
EV Over EBITDA
38.94
EV to Operating CashFlow
-46.57
EV to FreeCashFlow
-46.57
Earnings Yield
-2.25
FreeCashFlow Yield
-0.11
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0
Graham NetNet
-0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.06
ROE
0.37
Return On Assets
-3.32
Return On Capital Employed
0.11
Net Income per EBT
1
EBT Per Ebit
3.11
Ebit per Revenue
-6.25
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
6.58
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.5
Operating Profit Margin
-6.25
Pretax Profit Margin
-19.47
Net Profit Margin
-19.47

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.6
Return on Tangible Assets
-3.32
Days Sales Outstanding
215.22
Days Payables Outstanding
2857.32
Days of Inventory on Hand
3259.6
Receivables Turnover
1.7
Payables Turnover
0.13
Inventory Turnover
0.11
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
-0
Shareholders Equity per Share
-0
Interest Debt per Share
0
Debt to Equity
-0.81
Debt to Assets
7.57
Net Debt to EBITDA
31.39
Current Ratio
0.09
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-920903
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
76353
Debt to Market Cap
4.19

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Black Bird Biotech, Inc. Dividends
Year Dividends Growth

Black Bird Biotech, Inc. Profile

About Black Bird Biotech, Inc.

Black Bird Biotech Inc. provides various biotech products. It manufactures and distributes MiteXstream, a plant-based biopesticide for the eradication of spider mites. The company also manufactures and sells CBD Oils, gummies and pet treats, CBD-infused personal care products, and hand sanitizer gel and spray products under the Grizzly Creek Naturals brand name. In addition, it grows industrial hemp under the Montana Hemp pilot program. The company was formerly known as Digital Development Partners, Inc. and changed its name to Black Bird Biotech, Inc. in June 2021. Black Bird Biotech, Inc. is based in Flower Mound, Texas.

CEO
Mr. Nelson Grist
Employee
4
Address
3505 Yucca Drive
Flower Mound, 75028

Black Bird Biotech, Inc. Executives & BODs

Black Bird Biotech, Inc. Executives & BODs
# Name Age
1 Mr. Eric Newlan Esq.
Vice President, Secretary & Director
70
2 Mr. William J. LoBell
Executive Vice President of Sales & Development
70
3 Mr. Fabian G. Deneault
Chairman of the Board & President
70
4 Mr. Nelson Grist
Chief Executive Officer
70
5 Mr. William E. Sluss
Chief Financial Officer, Vice President of Finance & Director
70

Black Bird Biotech, Inc. Competitors